Deep Tide TechFlow news: On July 23, according to PRNewswire, Nasdaq-listed company Canton Strategic Holdings announced that it has completed the sale transaction of its biotechnology R&D division, Gravitas Life Sciences. The buyer is Gravitas Collective Corp. The transaction was unanimously approved by the company’s board of directors and was officially completed on July 17, 2026. This divestment marks the company’s further transformation into an operating business focused on driving the digitization of traditional financial markets around the Canton Network, advancing the tokenization of assets and digitization of financial markets, as well as its financial infrastructure business.

CC-0.54%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned